{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T20:03:24Z","timestamp":1774641804892,"version":"3.50.1"},"reference-count":150,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,11]],"date-time":"2021-04-11T00:00:00Z","timestamp":1618099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Regional Development Fund through the \u201cPrograma Operacional Regional do Centro (Centro 2020)\u2014Sistema de Apoio \u00e0 Investiga\u00e7\u00e3o Cient\u00edfica e Tecnol\u00f3gica\u2014Programas Integrados de IC&amp;DT (Covilh\u00e3)","award":["Centro-01-0145-FEDER-000019\u2014C4\u2014Centro de Compet\u00eancias em Cloud Computing"],"award-info":[{"award-number":["Centro-01-0145-FEDER-000019\u2014C4\u2014Centro de Compet\u00eancias em Cloud Computing"]}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/00709\/2020"],"award-info":[{"award-number":["UIDB\/00709\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04378\/2020"],"award-info":[{"award-number":["UIDP\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04378\/2020"],"award-info":[{"award-number":["UIDB\/04378\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BSAB\/150376\/2019"],"award-info":[{"award-number":["SFRH\/BSAB\/150376\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Neurodegenerative diseases (ND), including Alzheimer\u2019s (AD) and Parkinson\u2019s Disease (PD), are becoming increasingly more common and are recognized as a social problem in modern societies. These disorders are characterized by a progressive neurodegeneration and are considered one of the main causes of disability and mortality worldwide. Currently, there is no existing cure for AD nor PD and the clinically used drugs aim only at symptomatic relief, and are not capable of stopping neurodegeneration. Over the last years, several drug candidates reached clinical trials phases, but they were suspended, mainly because of the unsatisfactory pharmacological benefits. Recently, the number of compounds developed using in silico approaches has been increasing at a promising rate, mainly evaluating the affinity for several macromolecular targets and applying filters to exclude compounds with potentially unfavorable pharmacokinetics. Thus, in this review, an overview of the current therapeutics in use for these two ND, the main targets in drug development, and the primary studies published in the last five years that used in silico approaches to design novel drug candidates for AD and PD treatment will be presented. In addition, future perspectives for the treatment of these ND will also be briefly discussed.<\/jats:p>","DOI":"10.3390\/molecules26082193","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T05:52:00Z","timestamp":1618206720000},"page":"2193","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8552-6180","authenticated-orcid":false,"given":"Pedro","family":"Cruz-Vicente","sequence":"first","affiliation":[{"name":"CICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, Department of Chemistry, Faculty of Sciences and Technology, NOVA University Lisbon, 2829-516 Caparica, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6910-7576","authenticated-orcid":false,"given":"Lu\u00eds A.","family":"Passarinha","sequence":"additional","affiliation":[{"name":"CICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"UCIBIO\u2014Applied Molecular Biosciences Unit, Department of Chemistry, Faculty of Sciences and Technology, NOVA University Lisbon, 2829-516 Caparica, Portugal"},{"name":"Laboratory of Pharmaco-Toxicology\u2014UBIMedical, University of Beira Interior, 6200-001 Covilh\u00e3, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-5108","authenticated-orcid":false,"given":"Samuel","family":"Silvestre","sequence":"additional","affiliation":[{"name":"CICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"Laboratory of Pharmaco-Toxicology\u2014UBIMedical, University of Beira Interior, 6200-001 Covilh\u00e3, Portugal"},{"name":"CNC\u2014Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1802-8998","authenticated-orcid":false,"given":"Eugenia","family":"Gallardo","sequence":"additional","affiliation":[{"name":"CICS-UBI, Health Sciences Research Centre, University of Beira Interior, 6201-001 Covilh\u00e3, Portugal"},{"name":"Laboratory of Pharmaco-Toxicology\u2014UBIMedical, University of Beira Interior, 6200-001 Covilh\u00e3, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,11]]},"reference":[{"key":"ref_1","unstructured":"(2021, March 02). World Population Ageing [highlights], (n.d.). Available online: https:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/ageing\/WPA2017_Highlights.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Van Bulck, M., Sierra-Magro, A., Alarcon-Gil, J., Perez-Castillo, A., and Morales-Garcia, J. (2019). Novel Approaches for the Treatment of Alzheimer\u2019s and Parkinson\u2019s Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030719"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Feigin","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","article-title":"Dementia","volume":"131","author":"Gale","year":"2018","journal-title":"Am. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3233\/JPD-202128","article-title":"Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2020","volume":"10","author":"McFarthing","year":"2020","journal-title":"J. Parkinsons. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cummings, J., Lee, G., Ritter, A., Sabbagh, M., and Zhong, K. (2020). Alzheimer\u2019s disease drug development pipeline: 2020. Alzheimer\u2019s Dement. Transl. Res. Clin. Interv., 6.","DOI":"10.1002\/trc2.12050"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pro.3730","article-title":"RCSB Protein Data Bank: Enabling biomedical research and drug discovery","volume":"29","author":"Goodsell","year":"2020","journal-title":"Protein Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/1570159X16666180315142137","article-title":"Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design","volume":"16","author":"Sehgal","year":"2018","journal-title":"Curr. Neuropharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/B978-0-12-804766-8.00013-3","article-title":"Alzheimer\u2019s disease","volume":"Volume 167","year":"2019","journal-title":"Handbook of Clinical Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173554","DOI":"10.1016\/j.ejphar.2020.173554","article-title":"Alzheimer\u2019s disease: Recent treatment strategies","volume":"887","author":"Vaz","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.arr.2014.03.008","article-title":"Alzheimer\u2019s disease, enzyme targets and drug discovery struggles: From natural products to drug prototypes","volume":"15","author":"Silva","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbr.2010.11.058","article-title":"The cholinergic system in aging and neuronal degeneration","volume":"221","author":"Schliebs","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase Inhibitors: Pharmacology and Toxicology","volume":"11","author":"Colovic","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cbi.2010.01.042","article-title":"Acetylcholinesterase: From 3D structure to function","volume":"187","author":"Dvir","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nsb0197-57","article-title":"Structure of acetylcholinesterase complexed with the nootropic alkaloid, (\u2013)-huperzine A","volume":"4","author":"Raves","year":"1997","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"da Silva Mesquita, R., Kyrylchuk, A., Costa de Oliveira, R., Costa S\u00e1, I.S., Coutinho Borges Camargo, G., Soares Pontes, G., Moura Ara\u00fajo da Silva, F., de Saraiva Nunomura, R.C., and Grafov, A. (2020). Alkaloids of Abuta panurensis Eichler: In silico and in vitro study of acetylcholinesterase inhibition, cytotoxic and immunomodulatory activities. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239364"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.phymed.2017.12.020","article-title":"Cholinesterase-inhibitory effect and in silico analysis of alkaloids from bulbs of Hieronymiella species","volume":"39","author":"Ortiz","year":"2018","journal-title":"Phytomedicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"103124","DOI":"10.1016\/j.bioorg.2019.103124","article-title":"Flavonols and 4-thioflavonols as potential acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, structure-activity relationship and molecular docking studies","volume":"91","author":"Mughal","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chlebek, J., Kor\u00e1be\u010dn\u00fd, J., Dole\u017eal, R., \u0160t\u011bp\u00e1nkov\u00e1, \u0160., P\u00e9rez, D., Ho\u0161\u0165\u00e1lkov\u00e1, A., Opletal, L., Cahl\u00edkov\u00e1, L., Mac\u00e1kov\u00e1, K., and Ku\u010dera, T. (2019). In Vitro and In Silico Acetylcholinesterase Inhibitory Activity of Thalictricavine and Canadine and Their Predicted Penetration across the Blood-Brain Barrier. Molecules, 24.","DOI":"10.3390\/molecules24071340"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1080\/14756366.2018.1491847","article-title":"The insight of in vitro and in silico studies on cholinesterase inhibitors from the roots of Cimicifuga dahurica (Turcz.) Maxim","volume":"33","author":"Kim","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00894-017-3228-9","article-title":"Potential acetylcholinesterase inhibitors: Molecular docking, molecular dynamics, and in silico prediction","volume":"23","author":"Kiametis","year":"2017","journal-title":"J. Mol. Model."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e1800433","DOI":"10.1002\/cbdv.201800433","article-title":"Design and Synthesis of Selective Acetylcholinesterase Inhibitors: Arylisoxazole-Phenylpiperazine Derivatives","volume":"16","author":"Saeedi","year":"2019","journal-title":"Chem. Biodivers."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejmech.2019.05.039","article-title":"Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase","volume":"177","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.compbiolchem.2018.08.003","article-title":"Quinoline containing chalcone derivatives as cholinesterase inhibitors and their in silico modeling studies","volume":"76","author":"Shah","year":"2018","journal-title":"Comput. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103216","DOI":"10.1016\/j.bioorg.2019.103216","article-title":"Synthesis, in-vitro cholinesterase inhibition, in-vivo anticonvulsant activity and in-silico exploration of N-(4-methylpyridin-2-yl)thiophene-2-carboxamide analogs","volume":"92","author":"Ahmad","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.etap.2017.12.014","article-title":"In-silico and in-vitro evaluation of human acetylcholinesterase inhibition by organophosphates","volume":"57","author":"Ranjan","year":"2018","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1080\/07391102.2018.1505551","article-title":"In vitro and in silico evaluation of fucosterol from Sargassum horridum as potential human acetylcholinesterase inhibitor","volume":"37","author":"Bello","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.bmc.2018.01.029","article-title":"In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer\u2019s disease","volume":"26","author":"Gurjar","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ptr.6133","article-title":"Biological activities of extracts from Aspidosperma subincanum Mart. and in silico prediction for inhibition of acetylcholinesterase","volume":"32","author":"Pieters","year":"2018","journal-title":"Phyther. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11030-017-9732-0","article-title":"2D-SAR and 3D-QSAR analyses for acetylcholinesterase inhibitors","volume":"21","author":"Niu","year":"2017","journal-title":"Mol. Divers."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3233\/JAD-160763","article-title":"Role of Glutamate and NMDA Receptors in Alzheimer\u2019s Disease","volume":"57","author":"Wang","year":"2017","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","article-title":"Current and future treatments for Alzheimer\u2019s disease","volume":"6","author":"Yiannopoulou","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainresbull.2005.12.001","article-title":"Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study","volume":"69","author":"Shearman","year":"2006","journal-title":"Brain Res. Bull."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ivanova, L., Karelson, M., and Dobchev, D. (2018). Identification of Natural Compounds against Neurodegenerative Diseases Using In Silico Techniques. Molecules, 23.","DOI":"10.3390\/molecules23081847"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sharma, M., Mittal, A., Singh, A., Jainarayanan, A.K., Sharma, S., and Paliwal, S. (2020). Pharmacophore-driven identification of N-methyl-D-receptor antagonists as potent neuroprotective agents validated using in vivo studies. Biol. Methods Protoc., 5.","DOI":"10.1093\/biomethods\/bpaa013"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40409-017-0132-9","article-title":"In silico analysis of binding interaction of conantokins with NMDA receptors for potential therapeutic use in Alzheimer\u2019s disease","volume":"23","author":"Waqar","year":"2017","journal-title":"J. Venom. Anim. Toxins Incl. Trop. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Hu, S., Hu, H., Mak, S., Cui, G., Lee, M., Shan, L., Wang, Y., Lin, H., Zhang, Z., and Han, Y. (2018). A Novel Tetramethylpyrazine Derivative Prophylactically Protects against Glutamate-Induced Excitotoxicity in Primary Neurons through the Blockage of N-Methyl-D-aspartate Receptor. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00073"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kumar, S., Chowdhury, S., and Kumar, S. (2017). In silico repurposing of antipsychotic drugs for Alzheimer\u2019s disease. BMC Neurosci., 18.","DOI":"10.1186\/s12868-017-0394-8"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1080\/07391102.2019.1635530","article-title":"Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: An integrative in silico and molecular modeling approach","volume":"38","author":"Singh","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nature02621","article-title":"Pathways towards and away from Alzheimer\u2019s disease","volume":"430","author":"Mattson","year":"2004","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ddstr.2008.10.002","article-title":"Alzheimer\u2019s disease: \u03b3-secretase inhibitors","volume":"5","author":"Imbimbo","year":"2008","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmb.2010.10.054","article-title":"Inhibiting \u03b2-Secretase Activity in Alzheimer\u2019s Disease Cell Models with Single-Chain Antibodies Specifically Targeting APP","volume":"405","author":"Boddapati","year":"2011","journal-title":"J. Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","article-title":"The secretases: Enzymes with therapeutic potential in Alzheimer disease","volume":"6","author":"Vassar","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1326-2-22","article-title":"The Alzheimer\u2019s disease Beta-secretase enzyme, BACE1","volume":"2","author":"Cole","year":"2007","journal-title":"Mol. Neurodegener."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0197-4580(02)00122-7","article-title":"Emerging Alzheimer\u2019s disease therapies: Inhibition of \u03b2-secretase","volume":"23","author":"Citron","year":"2002","journal-title":"Neurobiol. Aging"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","article-title":"Developing \u03b2-secretase inhibitors for treatment of Alzheimer\u2019s disease","volume":"120","author":"Ghosh","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/med.21622","article-title":"BACE1 inhibitors: Current status and future directions in treating Alzheimer\u2019s disease","volume":"40","author":"Abdin","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jmgm.2017.07.010","article-title":"A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process","volume":"76","author":"Zuchniarz","year":"2017","journal-title":"J. Mol. Graph. Model."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1021\/acschemneuro.7b00416","article-title":"In Silico Identification and Experimental Validation of Novel Anti-Alzheimer\u2019s Multitargeted Ligands from a Marine Source Featuring a \u201c2-Aminoimidazole plus Aromatic Group\u201d Scaffold","volume":"9","author":"Vitale","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bbr.2018.08.010","article-title":"Neuroprotective effects of bergenin in Alzheimer\u2019s disease: Investigation through molecular docking, in vitro and in vivo studies","volume":"356","author":"Barai","year":"2019","journal-title":"Behav. Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lee, J., and Jun, M. (2019). Dual BACE1 and Cholinesterase Inhibitory Effects of Phlorotannins from Ecklonia cava\u2014An In Vitro and in Silico Study. Mar. Drugs, 17.","DOI":"10.3390\/md17020091"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kashyap, P., Kalaiselvan, V., Kumar, R., and Kumar, S. (2020). Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer\u2019s Disease. Molecules, 25.","DOI":"10.3390\/molecules25071609"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Han, J., Ji, Y., Youn, K., Lim, G., Lee, J., Kim, D.H., and Jun, M. (2019). Baicalein as a Potential Inhibitor against BACE1 and AChE: Mechanistic Comprehension through In Vitro and Computational Approaches. Nutrients, 11.","DOI":"10.3390\/nu11112694"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Lee, S., Youn, K., Lim, G., Lee, J., and Jun, M. (2018). In Silico Docking and In Vitro Approaches towards BACE1 and Cholinesterases Inhibitory Effect of Citrus Flavanones. Molecules, 23.","DOI":"10.3390\/molecules23071509"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Tran, T.-S., Tran, T.-D., Tran, T.-H., Mai, T.-T., Nguyen, N.-L., Thai, K.-M., and Le, M.-T. (2020). Synthesis, In Silico and In Vitro Evaluation of Some Flavone Derivatives for Acetylcholinesterase and BACE-1 Inhibitory Activity. Molecules, 25.","DOI":"10.3390\/molecules25184064"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102936","DOI":"10.1016\/j.bioorg.2019.102936","article-title":"Fluoro-benzimidazole derivatives to cure Alzheimer\u2019s disease: In-silico studies, synthesis, structure-activity relationship and in vivo evaluation for \u03b2 secretase enzyme inhibition","volume":"88","author":"Ali","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/bab.1570","article-title":"Biosynthesis of novel 7,8-dihydroxyflavone glycoside derivatives and in silico study of their effects on BACE1 inhibition","volume":"65","author":"Pandey","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"111707","DOI":"10.1016\/j.ejmech.2019.111707","article-title":"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer\u2019s disease","volume":"183","author":"Tripathi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bioorg.2017.07.014","article-title":"Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer\u2019s disease","volume":"74","author":"Haghighijoo","year":"2017","journal-title":"Bioorg. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tran, T.-S., Le, M.-T., Nguyen, T.-C.-V., Tran, T.-H., Tran, T.-D., and Thai, K.-M. (2020). Synthesis, In Silico and In Vitro Evaluation for Acetylcholinesterase and BACE-1 Inhibitory Activity of Some N-Substituted-4-Phenothiazine-Chalcones. Molecules, 25.","DOI":"10.3390\/molecules25173916"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/cbdd.13147","article-title":"In silico ligand-based modeling of h BACE-1 inhibitors","volume":"91","author":"Subramanian","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tran, T.-S., Le, M.-T., Tran, T.-D., Tran, T.-H., and Thai, K.-M. (2020). Design of Curcumin and Flavonoid Derivatives with Acetylcholinesterase and Beta-Secretase Inhibitory Activities Using in Silico Approaches. Molecules, 25.","DOI":"10.3390\/molecules25163644"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Coimbra, J.R.M., Baptista, S.J., Dinis, T.C.P., Silva, M.M.C., Moreira, P.I., Santos, A.E., and Salvador, J.A.R. (2020). Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors. Biomolecules, 10.","DOI":"10.3390\/biom10040535"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1332.001","article-title":"Targeting Amyloid-Degrading Enzymes as Therapeutic Strategies in Neurodegeneration","volume":"1035","author":"Turner","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"10323","DOI":"10.1002\/jcb.28316","article-title":"In silico identification of natural product inhibitors for \u03b3-secretase activating protein, a therapeutic target for Alzheimer\u2019s disease","volume":"120","author":"Gupta","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1021\/acschemneuro.9b00272","article-title":"Uncovering the Binding Mode of \u03b3 -Secretase Inhibitors","volume":"10","author":"Hitzenberger","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.pathol.4.110807.092250","article-title":"Mammalian Sirtuins: Biological Insights and Disease Relevance","volume":"5","author":"Haigis","year":"2010","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1093\/hmg\/ddr326","article-title":"The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS","volume":"20","author":"Maxwell","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1021\/jm3002108","article-title":"Design, Synthesis, and Biological Activity of a Novel Series of Human Sirtuin-2-Selective Inhibitors","volume":"55","author":"Suzuki","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/jm200590k","article-title":"Structure-Based Design of Pseudopeptidic Inhibitors for SIRT1 and SIRT2","volume":"54","author":"Huhtiniemi","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Furlan, V., Konc, J., and Bren, U. (2018). Inverse Molecular Docking as a Novel Approach to Study Anticarcinogenic and Anti-Neuroinflammatory Effects of Curcumin. Molecules, 23.","DOI":"10.3390\/molecules23123351"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"103403","DOI":"10.1016\/j.bioorg.2019.103403","article-title":"Discovery of gamma-mangostin from Garcinia mangostana as a potent and selective natural SIRT2 inhibitor","volume":"94","author":"Yeong","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/cdd.2014.216","article-title":"Old, new and emerging functions of caspases","volume":"22","author":"Shalini","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2174\/138161211795049705","article-title":"Matter of Life and Death: The Pharmacological Approaches Targeting Apoptosis in Brain Diseases","volume":"17","author":"Cavallucci","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"ref_77","first-page":"108","article-title":"Caspases as therapeutic targets in Alzheimer\u2019s disease: Is it time to \u201ccut\u201d to the chase?","volume":"2","author":"Rohn","year":"2009","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1038\/s41598-019-41930-7","article-title":"Identification of Allosteric Inhibitors against Active Caspase-6","volume":"9","author":"Beautrait","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Ahmad, S.S., Sinha, M., Ahmad, K., Khalid, M., and Choi, I. (2020). Study of Caspase 8 Inhibition for the Management of Alzheimer\u2019s Disease: A Molecular Docking and Dynamics Simulation. Molecules, 25.","DOI":"10.3390\/molecules25092071"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12013-020-00927-0","article-title":"\u2018Polymorphism-aided\u2019 Selective Targeting and Inhibition of Caspase-6 by a Novel Allosteric Inhibitor Towards Efficient Alzheimer\u2019s Disease Treatment","volume":"78","author":"Kumi","year":"2020","journal-title":"Cell Biochem. Biophys."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"172926","DOI":"10.1016\/j.ejphar.2020.172926","article-title":"Neuroprotective effects of novel nitrones: In vitro and in silico studies","volume":"871","author":"Cancela","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Kim, W.-Y., and Snider, W.D. (2011). Functions of GSK-3 Signaling in Development of the Nervous System. Front. Mol. Neurosci., 4.","DOI":"10.3389\/fnmol.2011.00044"},{"key":"ref_83","first-page":"1","article-title":"Deconstructing GSK-3: The Fine Regulation of Its Activity","volume":"2011","author":"Medina","year":"2011","journal-title":"Int. J. Alzheimers. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","article-title":"The GSK3 hypothesis of Alzheimer\u2019s disease","volume":"104","author":"Hooper","year":"2008","journal-title":"J. Neurochem."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Andreev, S., Pantsar, T., Ansideri, F., Kudolo, M., Forster, M., Schollmeyer, D., Laufer, S.A., and Koch, P. (2019). Design, Synthesis and Biological Evaluation of 7-Chloro-9H-pyrimido[4,5-b]indole-based Glycogen Synthase Kinase-3\u03b2 Inhibitors. Molecules, 24.","DOI":"10.3390\/molecules24122331"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.bmcl.2017.06.078","article-title":"Discovery of novel 2-(3-phenylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3\u03b2 inhibitors","volume":"27","author":"Usui","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Paudel, P., Seong, S., Zhou, Y., Park, C., Yokozawa, T., Jung, H., and Choi, J. (2018). Rosmarinic Acid Derivatives\u2019 Inhibition of Glycogen Synthase Kinase-3\u03b2 Is the Pharmacological Basis of Kangen-Karyu in Alzheimer\u2019s Disease. Molecules, 23.","DOI":"10.3390\/molecules23112919"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jmgm.2016.03.001","article-title":"Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor","volume":"65","author":"Nisha","year":"2016","journal-title":"J. Mol. Graph. Model."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejmech.2019.04.035","article-title":"Pyridinylimidazoles as dual glycogen synthase kinase 3\u03b2\/p38\u03b1 mitogen-activated protein kinase inhibitors","volume":"175","author":"Heider","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.bmc.2019.03.028","article-title":"Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3\u03b2 inhibitors","volume":"27","author":"Lozinskaya","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jmgm.2019.06.008","article-title":"Identification of novel small molecules against GSK3\u03b2 for Alzheimer\u2019s disease using chemoinformatics approach","volume":"91","author":"Shukla","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/cbdd.12913","article-title":"(Z)-2-(3-Chlorobenzylidene)-3,4-dihydro- N -(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3\u03b2 inhibitor: Identification by virtual screening and its validation in enzyme- and cell-based assay","volume":"89","author":"Joshi","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"107328","DOI":"10.1016\/j.compbiolchem.2020.107328","article-title":"In silico design novel (5-imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine derivatives as inhibitors for glycogen synthase kinase 3 based on 3D-QSAR, molecular docking and molecular dynamics simulation","volume":"88","author":"He","year":"2020","journal-title":"Comput. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10799893.2015.1122043","article-title":"E-pharmacophore-based virtual screening to identify GSK-3\u03b2 inhibitors","volume":"36","author":"Natarajan","year":"2016","journal-title":"J. Recept. Signal Transduct."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00894-019-4032-5","article-title":"Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3\u03b2 inhibitors","volume":"25","author":"Osman","year":"2019","journal-title":"J. Mol. Model."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12264-017-0183-5","article-title":"Biomarkers for Parkinson\u2019s Disease: Recent Advancement","volume":"33","author":"Lotankar","year":"2017","journal-title":"Neurosci. Bull."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1586\/ern.09.117","article-title":"Current strategies in the treatment of Parkinson\u2019s disease and a personalized approach to management","volume":"9","author":"Diaz","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Cacabelos, R. (2017). Parkinson\u2019s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18030551"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.parkreldis.2011.03.010","article-title":"Effect of intravenous amantadine on dopaminergic-drug-resistant freezing of gait","volume":"17","author":"Kim","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00002512-200016040-00003","article-title":"Tremor-Predominant Parkinson\u2019s Disease","volume":"16","author":"Koller","year":"2000","journal-title":"Drugs Aging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/nmt-2017-0028","article-title":"Parkinson\u2019s disease psychosis: Presentation, diagnosis and management","volume":"7","author":"Schneider","year":"2017","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/jnc.14713","article-title":"Antibodies against alpha-synuclein: Tools and therapies","volume":"150","author":"Vaikath","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"104712","DOI":"10.1016\/j.nbd.2019.104712","article-title":"Characterization of novel conformation-selective \u03b1-synuclein antibodies as potential immunotherapeutic agents for Parkinson\u2019s disease","volume":"136","author":"Henderson","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2011.20.1.1","article-title":"MAO-inhibitors in Parkinson\u2019s Disease","volume":"20","author":"Riederer","year":"2011","journal-title":"Exp. Neurobiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1517\/14656566.9.16.2759","article-title":"The increasing role of monoamine oxidase type B inhibitors in Parkinson\u2019s disease therapy","volume":"9","author":"Elmer","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_107","first-page":"31","article-title":"Safinamide: An add-on treatment for managing Parkinson\u2019s disease","volume":"10","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1111\/j.1742-4658.2011.08386.x","article-title":"The \u2018gating\u2019 residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition","volume":"278","author":"Milczek","year":"2011","journal-title":"FEBS J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"112305","DOI":"10.1016\/j.jep.2019.112305","article-title":"New role for crinamine as a potent, safe and selective inhibitor of human monoamine oxidase B: In vitro and in silico pharmacology and modeling","volume":"248","author":"Naidoo","year":"2020","journal-title":"J. Ethnopharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejmech.2019.04.016","article-title":"Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson\u2019s disease","volume":"173","author":"Tao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mehy.2018.06.009","article-title":"Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson\u2019s disease","volume":"117","author":"Mazumder","year":"2018","journal-title":"Med. Hypotheses"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2019.02.004","article-title":"Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies","volume":"27","author":"Schabikowski","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1021\/acschemneuro.7b00050","article-title":"Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson\u2019s Disease","volume":"8","author":"Nam","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Kozio\u0142, E., Luca, S.V., A\u011falar, H.G., Sa\u011fl\u0131k, B.N., Demirci, F., Marcourt, L., Wolfender, J.-L., J\u00f3\u017awiak, K., and Skalicka-Wo\u017aniak, K. (2020). Rutamarin: Efficient Liquid\u2013Liquid Chromatographic Isolation from Ruta graveolens L. and Evaluation of Its In Vitro and In Silico MAO-B Inhibitory Activity. Molecules, 25.","DOI":"10.3390\/molecules25112678"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.compbiolchem.2019.01.012","article-title":"Synthesis, monoamine oxidase inhibitory activity and computational study of novel isoxazole derivatives as potential antiparkinson agents","volume":"79","author":"Agrawal","year":"2019","journal-title":"Comput. Biol. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Dhiman, P., Malik, N., and Khatkar, A. (2019). Lead optimization for promising monoamine oxidase inhibitor from eugenol for the treatment of neurological disorder: Synthesis and in silico based study. BMC Chem., 13.","DOI":"10.1186\/s13065-019-0552-4"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14756366.2019.1571272","article-title":"4-(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives as antioxidants and selective hMAO-B inhibitors: Synthesis, biological activity and computational analysis","volume":"34","author":"Secci","year":"2019","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chaurasiya, N., Zhao, J., Pandey, P., Doerksen, R., Muhammad, I., and Tekwani, B. (2019). Selective Inhibition of Human Monoamine Oxidase B by Acacetin 7-Methyl Ether Isolated from Turnera diffusa (Damiana). Molecules, 24.","DOI":"10.3390\/molecules24040810"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1021\/acschemneuro.8b00095","article-title":"Proposing Novel MAO-B Hit Inhibitors Using Multidimensional Molecular Modeling Approaches and Application of Binary QSAR Models for Prediction of Their Therapeutic Activity, Pharmacokinetic and Toxicity Properties","volume":"9","author":"Is","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1021\/acs.jmedchem.0c01663","article-title":"Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor","volume":"63","author":"Jin","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_121","first-page":"1117","article-title":"Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B\/A2AAR Dual Binding Scaffold","volume":"15","author":"Borges","year":"2017","journal-title":"Curr. Neuropharm."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1021\/acs.jcim.6b00608","article-title":"Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2 H -Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure\u2013Activity Relationships Predictive Models","volume":"57","author":"Patsilinakos","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"ref_123","first-page":"1","article-title":"Dopamine Receptors and Parkinson\u2019s Disease","volume":"2011","author":"Hisahara","year":"2011","journal-title":"Int. J. Med. Chem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/jnnp.68.6.685","article-title":"Dopamine agonists: Their role in the treatment of Parkinson\u2019s disease","volume":"68","author":"Brooks","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson\u2019s disease: Etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Paudel, P., Seong, S.H., Wu, S., Park, S., Jung, H.A., and Choi, J.S. (2019). Eckol as a Potential Therapeutic against Neurodegenerative Diseases Targeting Dopamine D3\/D4 Receptors. Mar. Drugs, 17.","DOI":"10.3390\/md17020108"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"108757","DOI":"10.1016\/j.cbi.2019.108757","article-title":"Characterizing fucoxanthin as a selective dopamine D3\/D4 receptor agonist: Relevance to Parkinson\u2019s disease","volume":"310","author":"Paudel","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Paudel, P., Park, S.E., Seong, S.H., Jung, H.A., and Choi, J.S. (2019). Novel Diels\u2013Alder Type Adducts from Morus alba Root Bark Targeting Human Monoamine Oxidase and Dopaminergic Receptors for the Management of Neurodegenerative Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246232"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ejmech.2016.08.051","article-title":"Design, synthesis and preliminary evaluation of dopamine-amino acid conjugates as potential D1 dopaminergic modulators","volume":"124","author":"Tutone","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cbdd.12743","article-title":"Computational Study and Modified Design of Selective Dopamine D 3 Receptor Agonists","volume":"88","author":"Duan","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1016\/j.bmcl.2012.07.003","article-title":"High-affinity and selective dopamine D3 receptor full agonists","volume":"22","author":"Chen","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/acschemneuro.8b00313","article-title":"Development of Adenosine A 2A Receptor Antagonists for the Treatment of Parkinson\u2019s Disease: A Recent Update and Challenge","volume":"10","author":"Zheng","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1021\/acs.chemrev.6b00119","article-title":"Structurally Enabled Discovery of Adenosine A 2A Receptor Antagonists","volume":"117","author":"Jazayeri","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1021\/acs.jmedchem.7b00457","article-title":"The 1,2,4-Triazolo[4,3- a ]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A 2A Receptor Subtype","volume":"60","author":"Falsini","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bioorg.2019.03.032","article-title":"Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A2A AR ligands with in vivo efficacy against animal model of Parkinson\u2019s disease","volume":"87","author":"Rohilla","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1021\/acschemneuro.6b00218","article-title":"Identification of a New Series of Potent Adenosine A 2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson\u2019s Disease","volume":"7","author":"Yang","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"103459","DOI":"10.1016\/j.bioorg.2019.103459","article-title":"Synthesis and evaluation of methoxy substituted 2-benzoyl-1-benzofuran derivatives as lead compounds for the development adenosine A1 and\/or A2A receptor antagonists","volume":"94","author":"Legoabe","year":"2020","journal-title":"Bioorg. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1527-3458.2007.00020.x","article-title":"Catechol-O-methyltransferase and Its Inhibitors in Parkinson\u2019s Disease","volume":"13","author":"Palma","year":"2007","journal-title":"CNS Drug Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1021\/jm500572b","article-title":"Medicinal Chemistry of Catechol O Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility","volume":"57","author":"Kiss","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14740338.2018.1433659","article-title":"The launch of opicapone for Parkinson\u2019s disease: Negatives versus positives","volume":"17","author":"Teodoro","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bcp.12169","article-title":"Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders","volume":"77","author":"Ma","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/acs.jmedchem.6b00666","article-title":"Development of Blood\u2013Brain Barrier Permeable Nitrocatechol-Based Catechol O -Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity","volume":"59","author":"Silva","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"de Beer, J., Petzer, J.P., Lourens, A.C.U., and Petzer, A. (2020). Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase. Mol. Divers., 1\u201310.","DOI":"10.1007\/s11030-020-10053-x"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cbi.2016.06.005","article-title":"Combining in vitro and in silico approaches to evaluate the multifunctional profile of rosmarinic acid from Blechnum brasiliense on targets related to neurodegeneration","volume":"254","author":"Andrade","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bjp.2015.07.002","article-title":"The catechol-O-methyltransferase inhibitory potential of Z-vallesiachotamine by in silico and in vitro approaches","volume":"25","author":"Henriques","year":"2015","journal-title":"Rev. Bras. Farmacogn."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"171271","DOI":"10.1098\/rsos.171271","article-title":"In vitro evaluation of the effect of C-4 substitution on methylation of 7,8-dihydroxycoumarin: Metabolic profile and catalytic kinetics","volume":"5","author":"Xia","year":"2018","journal-title":"R. Soc. Open Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.fct.2019.03.049","article-title":"The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase","volume":"128","author":"Verdura","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Govindasamy, H., Magudeeswaran, S., and Poomani, K. (2019). Identification of novel flavonoid inhibitor of Catechol-O-Methyltransferase enzyme by molecular screening, quantum mechanics\/molecular mechanics and molecular dynamics simulations. J. Biomol. Struct. Dyn., 1\u201313.","DOI":"10.1080\/07391102.2019.1699446"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1080\/07391102.2017.1404931","article-title":"Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer\u2019s disease","volume":"36","author":"Patel","year":"2018","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1021\/acs.jmedchem.6b00927","article-title":"Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O -Methyltransferase Derived from a Fragment Screening Approach Targeting the S -Adenosyl- l -methionine Pocket","volume":"59","author":"Lerner","year":"2016","journal-title":"J. Med. Chem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/8\/2193\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:27:59Z","timestamp":1760365679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/8\/2193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,11]]},"references-count":150,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["molecules26082193"],"URL":"https:\/\/doi.org\/10.3390\/molecules26082193","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,11]]}}}